Stem Cell Therapy for Hearing Loss

What This Article Covers

This article explains why sensorineural hearing loss cannot currently be reversed with standard medical care, why researchers believe stem cells and related regenerative cell therapies might one day change that, and exactly how far the science has actually progressed — including the first-ever human trial of a regenerative cell therapy for this condition, approved in the UK in 2025. No stem cell treatment for hearing loss is approved by the FDA, the EMA, or any other regulator; everything described here is investigational.

Sensorineural hearing loss (SNHL) is the most common form of permanent hearing loss, caused by damage to the tiny sound-sensing hair cells of the inner ear (cochlea) or to the auditory nerve fibers that carry sound signals to the brain. It can result from aging (presbycusis), noise exposure, certain medications, infections, or genetic factors. Globally, hearing loss affects well over a billion people, with hundreds of millions living with disabling hearing loss according to the World Health Organization — a number projected to grow substantially by mid-century. Unlike some other tissues in the body, human cochlear hair cells and auditory neurons do not regenerate once lost. Standard care today — hearing aids and cochlear implants — can amplify or electronically substitute for sound, but cannot restore the biological cells themselves. That is the gap regenerative medicine researchers are trying to close.

How It's Thought to Work

Researchers are pursuing several overlapping strategies. One approach uses stem cell–derived or lab-grown otic progenitor cells that, once introduced into the inner ear, are designed to develop into new auditory neurons or hair cells and reestablish the connections needed to transmit sound signals to the brain. A second approach uses mesenchymal stem cells (MSCs), prized less for becoming new inner-ear cells themselves and more for their anti-inflammatory and paracrine (signaling) effects — the idea being that they might protect surviving cells or calm inflammation that contributes to hearing decline. A third, more basic-science line of work focuses on identifying and activating dormant progenitor cells already present in the cochlea, coaxing them to divide and mature into functional hair cells, an approach that has shown promise in mouse and other animal models but has proven very difficult to scale to the human ear, which is minute and largely inaccessible without surgery.

What the Evidence Shows

The evidence base here is still overwhelmingly preclinical. A 2025 systematic review published in Cureus examined eight qualifying studies using various stem cell types — embryonic, umbilical cord, and inner ear-derived cells — delivered either intravenously or directly into the inner ear. The review found that nearly all of this work was done in animal models, with only one study involving human subjects, and that results on hearing improvement were mixed: some studies reported meaningful gains in hearing thresholds while others showed no measurable effect. The single human study identified no significant adverse effects, but the authors concluded that larger, standardized human trials are still needed before safety and effectiveness can be established.

Foundational laboratory work has also mattered a great deal in getting the field this far. Research from the Harvard Stem Cell Institute, including work by Dr. Albert Edge's laboratory, identified a way to dramatically expand a population of cochlear stem cells and coax them into functional hair cells in mice, non-human primates, and human tissue samples — a scientific milestone that helped catalyze commercial interest in hair-cell regeneration, though it is worth noting that at least one company's attempt to translate similar science into a human drug (Frequency Therapeutics' FX-322) failed to show benefit in a Phase 2b trial, underscoring how far basic science is from a working treatment.

The most significant recent development is genuinely exciting: in 2025, the University of Sheffield announced that the world's first human clinical trial of a regenerative cell therapy for sensorineural hearing loss had been approved. The therapy, called Rincell-1, was developed by Rinri Therapeutics (a University of Sheffield spinout) and consists of lab-grown otic neural progenitor cells designed to regenerate damaged auditory neurons. The Phase I/IIa first-in-human trial will enroll about 20 patients across two groups — those with postsynaptic auditory neuropathy spectrum disorder and those with severe-to-profound age-related hearing loss — with roughly half receiving Rincell-1 alongside a cochlear implant and half receiving the implant alone, followed for up to a year. This is, first and foremost, a safety study: its goal is to establish that the therapy is safe and tolerable, not to prove it restores hearing, and researchers themselves note there is no guarantee of therapeutic benefit. Separately, a U.S.-based study listed on ClinicalTrials.gov (NCT07472023), sponsored by Truway Health, is an early Phase 1, invitation-only program exploring stem cell and pharmacologic regenerative approaches across several inner ear conditions, including noise-induced and sudden sensorineural hearing loss and tinnitus — another sign that human-stage research in this space is just beginning, not concluding.

Who Might Be a Candidate

• There is currently no FDA- or EMA-approved stem cell treatment for hearing loss, so there is no real-world "candidacy" for this therapy outside of formal clinical research.
• The only way to access these therapies today is through enrollment in an approved clinical trial, such as the Rinri Therapeutics Rincell-1 study or similar registered trials.
• Trial eligibility is typically narrow and condition-specific — for example, the current Rincell-1 trial is enrolling people with postsynaptic auditory neuropathy or severe-to-profound age-related hearing loss, often alongside cochlear implant candidacy.
• Anyone interested in participating should look for actively recruiting studies on ClinicalTrials.gov and discuss eligibility, risks, and realistic expectations with a qualified ear, nose, and throat (ENT) specialist or audiologist.
• People should be highly cautious of any clinic marketing "stem cell hearing loss treatments" outside of a registered clinical trial, since no such treatment has regulatory approval anywhere in the world.

Bottom Line

For decades, the idea of regrowing the cells that make hearing possible existed only in petri dishes and mouse studies. The approval of the first human trial of a regenerative cell therapy for sensorineural hearing loss is a real and encouraging milestone — proof that the underlying science has matured enough to be tested, cautiously, in people. But it is only the first step of a long process. This and other early trials are designed primarily to test safety, not to prove that hearing can be restored, and it will likely be years before regulators have enough evidence to consider approving any such therapy — if the evidence ultimately supports it at all. Anyone affected by sensorineural hearing loss should continue to rely on proven options like hearing aids and cochlear implants, monitor legitimate clinical trial registries for developments, and treat any commercial "stem cell cure" claim for hearing loss with skepticism, since none is currently backed by regulatory approval.